Similar results were obtained by Munzone E. et al. [29] in a study with 203 patients divided by CTC number into 3 prognostic subgroups: 0 CTC, 1–4 CTC, and ≥5 CTC in 7.5 mL blood, and they were also divided into 5 categories based on tumor characteristics, as follows: luminal A (27 patients), luminal B (105 patients), luminal B- HER2+ (29 patients), HER2+ (24 patients), and TNBC (18 patients). The gene discussed is ERBB2; the disease is neoplasm.